Phase II studies of bleomycin, ifosfamide and cis-platinum in advanced and recurrent cervical carcinoma.
We report the results of phase II studies using a combination of ifosfamide, cis-platinum and bleomycin (BIP) in advanced and recurrent cervical cancer. Fifty-one patients have been studied. In 37 patients with disease not amenable to radical local therapy 27 objective responses (73%) were seen with 7 complete responses. Eleven of 14 patients (79%) with primary inoperable disease had at least a 50% reduction in tumour bulk prior to radical local radiotherapy. All patients experienced alopecia, nausea and vomiting. Other toxicity included myelosuppression, infection, reduction in renal function and disturbance of consciousness. There was no evidence that primary chemotherapy enhanced the acute toxic effects of pelvic radiotherapy. These data indicate that BIP is highly active in cervical cancer and can be used for effective palliation and cytoreduction in more than 70% of patients.
Buxton
E J
EJ
West Midlands Cancer Research Campaign Clinical Trials Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham, England.
Meanwell
C A
CA
Mould
J J
JJ
Latief
T
T
Chetiyawardana
A D
AD
Spooner
D
D
Tobias
J S
JS
Sokal
M
M
Alcock
C
C
Hilton
C
C
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality
D001761:Bleomycin; D002945:Cisplatin; D007069:Ifosfamide